CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
MEDI7183 low dose +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01959165
NCT01959165Phase 2Completed
CompareCT.gov

MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients

AstraZeneca·interventional·Posted Oct 9, 2013·Updated Jul 5, 2019

In Brief

A Phase 2 clinical trial evaluating MEDI7183 low dose, MEDI7183 medium dose, and 2 other interventions for Ulcerative Colitis. Completed, enrolled 44 participants across 23 sites.

Detailed Summary

This is a multi-centre, randomised, double-blind, placebo controlled, parallel group, Phase II study to evaluate efficacy and safety of 3 doses of MEDI7183, in Japanese subjects with moderate to severe UC

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 9, 2013
Enrollment StartNov 21, 2013
Primary CompletionAug 11, 2015
Study CompletionApr 10, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 12.7 years ago

Interventions

MEDI7183 low dosedrug

MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8

MEDI7183 medium dosedrug

MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8

MEDI7183 high dosedrug

MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8

Matching Placebodrug

Placebo will be administered by SC on Day 1, Week 2,4, and 8